Characteristics of NIH chronic GVHD at onset
| Characteristic, n (%) . | BMT . | PBSCT . | ||||
|---|---|---|---|---|---|---|
| Japanese (n = 41) . | White (n = 21) . | P . | Japanese (n = 35) . | White (n = 286) . | P . | |
| Months from transplantation to NIH chronic GVHD, median (IQR) | 6.9 (5.5-9.6) | 7.8 (4.7-10.5) | .91 | 6.0 (4.2-9.5) | 7.2 (4.6-11.7) | .39 |
| Type | .09 | <.001 | ||||
| De novo | 16 (39) | 5 (24) | 19 (54) | 63 (22) | ||
| Quiescent | 21 (51) | 16 (76) | 11 (31) | 197 (69) | ||
| Progressive | 4 (10) | 0 (0) | 5 (14) | 26 (9) | ||
| Sites involved | ||||||
| Skin | 27 (66) | 13 (62) | .79 | 22 (63) | 211 (74) | .23 |
| Mouth | 33 (80) | 13 (62) | .14 | 31 (89) | 197 (69) | .017 |
| Eyes | 24 (59) | 4 (19) | .004 | 23 (66) | 102 (36) | .001 |
| Gastrointestinal tract | 2 (5) | 7 (33) | .005 | 9 (26) | 117 (41) | .10 |
| Liver | 32 (78) | 9 (43) | .01 | 32 (91) | 129 (45) | <.001 |
| Lung (bronchiolitis obliterans) | 1 (2) | 1 (5) | 1.0 | 2 (6) | 3 (1) | .094 |
| Joint/fascia | 1 (2) | 1 (5) | 1.0 | 1 (3) | 39 (14) | .10 |
| Genital | 5 (12) | 2 (10) | 1.0 | 3 (9) | 23 (8) | 1.0 |
| NIH global severity score | .37 | .03 | ||||
| Mild | 2 (5) | 3 (14) | 0 (0) | 11 (4) | ||
| Moderate | 20 (49) | 11 (52) | 12 (34) | 154 (54) | ||
| Severe | 19 (46) | 7 (33) | 23 (66) | 121 (42) | ||
| No. of involved sites | .024 | .025 | ||||
| 1 or 2 | 9 (22) | 12 (57) | 8 (23) | 128 (45) | ||
| 3 | 21 (51) | 6 (29) | 10 (29) | 72 (25) | ||
| ≥4 | 11 (27) | 3 (14) | 17 (49) | 86 (30) | ||
| Prior IIb-IV classic or late acute GVHD | 17 (41) | 8 (38) | 1.0 | 10 (29) | 121 (42) | .15 |
| Karnofsky Performance Status | .37 | .085 | ||||
| 80-100% | 32 (78) | 14 (67) | 28 (80) | 174 (61) | ||
| <80% | 9 (22) | 7 (33) | 7 (20) | 111 (39) | ||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (< 1) | ||
| Dose of prednisone, mg/kg | .20 | .78 | ||||
| None | 31 (76) | 19 (90) | 29 (83) | 232 (81) | ||
| >0 but <0.5 | 10 (24) | 2 (10) | 4 (11) | 41 (14) | ||
| 0.5-1.0 | 0 (0) | 0 (0) | 2 (6) | 12 (4) | ||
| >1.0 | 0 (0) | 0 (0) | 0 (0) | 1 (< 1) | ||
| Platelet count <100 × 109/L | 17 (41) | 8 (38) | 1.0 | 11 (31) | 68 (24) | .31 |
| Serum bilirubin level >2 mg/dL | 1 (2) | 0 (0) | 1.0 | 3 (9) | 10 (4) | .16 |
| Characteristic, n (%) . | BMT . | PBSCT . | ||||
|---|---|---|---|---|---|---|
| Japanese (n = 41) . | White (n = 21) . | P . | Japanese (n = 35) . | White (n = 286) . | P . | |
| Months from transplantation to NIH chronic GVHD, median (IQR) | 6.9 (5.5-9.6) | 7.8 (4.7-10.5) | .91 | 6.0 (4.2-9.5) | 7.2 (4.6-11.7) | .39 |
| Type | .09 | <.001 | ||||
| De novo | 16 (39) | 5 (24) | 19 (54) | 63 (22) | ||
| Quiescent | 21 (51) | 16 (76) | 11 (31) | 197 (69) | ||
| Progressive | 4 (10) | 0 (0) | 5 (14) | 26 (9) | ||
| Sites involved | ||||||
| Skin | 27 (66) | 13 (62) | .79 | 22 (63) | 211 (74) | .23 |
| Mouth | 33 (80) | 13 (62) | .14 | 31 (89) | 197 (69) | .017 |
| Eyes | 24 (59) | 4 (19) | .004 | 23 (66) | 102 (36) | .001 |
| Gastrointestinal tract | 2 (5) | 7 (33) | .005 | 9 (26) | 117 (41) | .10 |
| Liver | 32 (78) | 9 (43) | .01 | 32 (91) | 129 (45) | <.001 |
| Lung (bronchiolitis obliterans) | 1 (2) | 1 (5) | 1.0 | 2 (6) | 3 (1) | .094 |
| Joint/fascia | 1 (2) | 1 (5) | 1.0 | 1 (3) | 39 (14) | .10 |
| Genital | 5 (12) | 2 (10) | 1.0 | 3 (9) | 23 (8) | 1.0 |
| NIH global severity score | .37 | .03 | ||||
| Mild | 2 (5) | 3 (14) | 0 (0) | 11 (4) | ||
| Moderate | 20 (49) | 11 (52) | 12 (34) | 154 (54) | ||
| Severe | 19 (46) | 7 (33) | 23 (66) | 121 (42) | ||
| No. of involved sites | .024 | .025 | ||||
| 1 or 2 | 9 (22) | 12 (57) | 8 (23) | 128 (45) | ||
| 3 | 21 (51) | 6 (29) | 10 (29) | 72 (25) | ||
| ≥4 | 11 (27) | 3 (14) | 17 (49) | 86 (30) | ||
| Prior IIb-IV classic or late acute GVHD | 17 (41) | 8 (38) | 1.0 | 10 (29) | 121 (42) | .15 |
| Karnofsky Performance Status | .37 | .085 | ||||
| 80-100% | 32 (78) | 14 (67) | 28 (80) | 174 (61) | ||
| <80% | 9 (22) | 7 (33) | 7 (20) | 111 (39) | ||
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (< 1) | ||
| Dose of prednisone, mg/kg | .20 | .78 | ||||
| None | 31 (76) | 19 (90) | 29 (83) | 232 (81) | ||
| >0 but <0.5 | 10 (24) | 2 (10) | 4 (11) | 41 (14) | ||
| 0.5-1.0 | 0 (0) | 0 (0) | 2 (6) | 12 (4) | ||
| >1.0 | 0 (0) | 0 (0) | 0 (0) | 1 (< 1) | ||
| Platelet count <100 × 109/L | 17 (41) | 8 (38) | 1.0 | 11 (31) | 68 (24) | .31 |
| Serum bilirubin level >2 mg/dL | 1 (2) | 0 (0) | 1.0 | 3 (9) | 10 (4) | .16 |